Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?

J Clin Oncol. 2003 Jun 15;21(12):2227-9. doi: 10.1200/JCO.2003.04.001. Epub 2003 May 14.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Clinical Trials, Phase II as Topic
  • Epidermal Growth Factor / antagonists & inhibitors*
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Quinazolines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Epidermal Growth Factor
  • Gefitinib